癌症是影响人类健康的主要疾病之一,其发病率和死亡率等数据的准确统计对于开展疾病预防及制定干预策略极为重要。GLOBOCAN是国际癌症研究机构(International Agency for Research on Cancer,IARC)的一个项目,统计了世界上185个国家/地...癌症是影响人类健康的主要疾病之一,其发病率和死亡率等数据的准确统计对于开展疾病预防及制定干预策略极为重要。GLOBOCAN是国际癌症研究机构(International Agency for Research on Cancer,IARC)的一个项目,统计了世界上185个国家/地区中的36种癌症发病率、死亡率和患病率等相关数据,并且数据会不断更新,为研究者做疾病预测及疾病负担分析提供了宝贵的资料。本文通过对GLOBOCAN数据库架构及数据分析方法的详细介绍,帮助需要的研究者快速获取数据库相关知识,高效快捷地开展相关研究。展开更多
2024年2月国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了最新的全球癌症统计数据GLOBOCAN 2022,估计了全球185个国家/地区的36种癌症发病数/率、死亡数/率等最新数据,描述了不同国家/地区和性别下的癌症...2024年2月国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了最新的全球癌症统计数据GLOBOCAN 2022,估计了全球185个国家/地区的36种癌症发病数/率、死亡数/率等最新数据,描述了不同国家/地区和性别下的癌症负担差异,并对至2050年的癌症负担进行了预测。GLOBOCAN 2022数据显示,2022年全球估计新发癌症19976499例,9743832例癌症患者死亡。肺癌是全球首位常见癌症,2022年发病例数为2480675例,占总体癌症发病的12.4%。其次是乳腺癌(11.5%)、结直肠癌(9.6%)、前列腺癌(7.3%)和胃癌(4.9%)。肺癌仍是导致癌症死亡的首要原因,估计有1817469例死亡,占总体癌症死亡的18.7%。其次是结直肠癌(9.3%)、肝癌(7.8%)、乳腺癌(6.8%)和胃癌(6.8%)。基于人口统计学的预测表明,到2050年,全球新增癌症病例将达到3528.1万例,与2022年相比增加76.6%。全球癌症发病和死亡具有明显的地区和性别差异。本文对更新的数据库中主要内容进行整理并加以解读。展开更多
Background:The International Agency for Research on Cancer(IARC)released the latest estimates of the global burden of cancer.We present a comparison of cancer profiles between 2020 and 2022,leveraging data from the Gl...Background:The International Agency for Research on Cancer(IARC)released the latest estimates of the global burden of cancer.We present a comparison of cancer profiles between 2020 and 2022,leveraging data from the Global Cancer Statistics(GLOBOCAN).Methods:Cancer incidence and mortality data were sourced from two different years,2020 and 2022,in the GLOBOCAN database.We tracked changes in age-standardized incidence and mortality rates,as well as estimated numbers of new cancer cases and deaths of the 15 most common cancer types globally and in China between 2020 and 2022.Additionally,we conducted comparisons to assess alterations in the cancer burden and variations in mortality-to-incidence ratio(MIR)across different regions and countries for both 2020 and 2022.Results:Lung cancer remained the most common cancer and the leading cause of cancer death worldwide.The new cases of thyroid cancer witnessed a sharp increase in 2022.Conversely,the numbers of new cancer cases and deaths from stomach and esophageal cancer decreased significantly in 2022.The geographic distribution of cancer incidence and mortality across six continents in 2022 largely mirrored that of 2020.Higher Human Development Index(HDI)levels in countries corresponded with elevated rates of cancer incidence and mortality,consistent with the previous year.Among 185 countries or territories,China’s age-standardized incidence rate(ASIR)ranked 64th and its age-standardized mortality rate(ASMR)ranked 68th,aligning with global averages.Lung cancer continued to impose the greatest burden of incidence and mortality.Stomach,breast,and esophageal cancers showed declines in both case counts and ASIR.Noteworthy reductions in both ASMR and absolute mortality numbers were observed in liver,stomach,and esophageal cancers.The global MIR decreased from 0.516 in 2020 to 0.488 in 2022.MIR trends indicated an upward trajectory with decreasing HDI levels in both 2022 and 2020.While Canada,Germany,India,Italy,Japan,and the United Kingdom demonstrated increasing MIRs,China exhibited the most significant decrease,followed by Russia and the United States.Conclusions:The global landscape of cancer incidence and mortality in 2022 reflects ongoing trends observed in 2020.Cancer burdens vary notably across countries with differing socioeconomic statuses.Decreases in stomach,liver,and esophageal cancer cases and deaths signify progress in cancer control efforts.The decrease in the global MIRs highlights potential improvements in cancer management.展开更多
Background:Thyroid cancer(TC)is the most common malignancy of the endocrine system.This study aimed to assess the global distribution of TC incidence and mortality in 2022,as well as to predict the burden for the year...Background:Thyroid cancer(TC)is the most common malignancy of the endocrine system.This study aimed to assess the global distribution of TC incidence and mortality in 2022,as well as to predict the burden for the year 2050.Methods:Data from the GLOBOCAN 2022 database were used to analyze the age-standardized incidence and mortality rates of TC by sex,age group(<55 years and≥55 years),country,world region,and level of Human Development Index(HDI)for 185 countries.The predicted incidence and mortality burden for 2050 was calculated based on demographic projections.Results:In 2022,an estimated 821,214 new TC cases and 47,507 TC-related deaths occurred worldwide.The age-standardized incidence rates(ASIRs)and age-standardized mortality rates(ASMRs)were higher in women(ASIR:13.60 per 100,000;ASMR:0.53 per 100,000)than in men(ASIR:4.60 per 100,000;ASMR:0.35 per 100,000).The ASIR in high HDI countries was approximately ten times higher than that in low HDI countries for both sexes,with relatively similar ASMR across regions.Among 185 countries,China had the largest number of TC cases(accounting for 56.77% of total cases)and TC-related deaths(accounting for 24.35% of global TC-related deaths),with the highest ASIR in men(13.30 per 100,000).Worldwide,approximately 64.63% of TC cases occurred in populations under 55 years old,while nearly 82.99% of TC-related deaths occurred in populations aged 55 years and above.If the rates stay the same as in 2022,it is projected that approximately 1,100,000 new TC cases and 91,000 TC-related deaths will occur in 2050,indicating a 34.15% and 89.58% increase,respectively.Conclusions:TC is a highly frequent cancer worldwide with disparities across regions,genders,and age groups.Our results provide light on the worldwide TC disease burden and facilitate regionally customized prevention measures.展开更多
目的 基于国际癌症研究机构发布的GLOBOCAN 2018、2020及2022版本,系统分析2018–2022年间全球及中国胰腺癌的发病和死亡情况,并总结其主要影响因素,为我国胰腺癌的防控策略制定与临床诊疗实践提供参考。方法 收集并整理GLOBOCAN数据库...目的 基于国际癌症研究机构发布的GLOBOCAN 2018、2020及2022版本,系统分析2018–2022年间全球及中国胰腺癌的发病和死亡情况,并总结其主要影响因素,为我国胰腺癌的防控策略制定与临床诊疗实践提供参考。方法 收集并整理GLOBOCAN数据库中胰腺癌的发病例数、死亡例数,以及粗发病率、粗死亡率、世界年龄标准化发病率(age-standardized incidence rate by world standard population,ASIRW)、世界年龄标准化死亡率(age-standardized mortality rate by world standard population,ASMRW)等指标;同时结合人类发展指数(human development index,HDI)、国家收入水平等社会经济学参数,对全球与中国胰腺癌在不同地区、不同年龄与不同性别中的分布特点进行比较分析。结果 从2018年至2022年,全球胰腺癌新发病例数由45.8万增至51.1万,粗发病率从5.4/10万上升至6.5/10万;死亡例数从43.2万上升至46.7万,粗死亡率从5.7/10万增至5.9/10万,ASMRW从4.4/10万下降至4.3/10万。中国胰腺癌新发病例数从11.6万增至11.9万,占全球的23.3%,粗发病率维持在(8~9)/10万;死亡例数从11.0万下降至10.6万,粗死亡率从7.8/10万降至7.5/10万,ASMRW从4.9/10万降至3.9/10万。2022年非常高HDI国家的胰腺癌ASIRW为7.9/10万,ASMRW为6.9/10万,远高于低HDI国家的1.4/10万、1.3/10万。胰腺癌发病呈明显年龄相关性,≥75岁组全球新发191 157例(粗发病率为63.3/10万),中国新发37 722例(粗发病率为51.2/10万);全球和中国的男性发病率和死亡率均高于女性。结论 胰腺癌正成为全球和中国重要的公共卫生挑战,其发病与死亡在未来仍可能继续攀升。应进一步加强控烟、肥胖管理、糖尿病监测等综合防控措施;针对高危人群开展早期筛查及规范化诊治对于提升胰腺癌生存率至关重要。完善全国肿瘤登记体系,并结合多学科协作模式,可为精准防治胰腺癌奠定坚实基础。展开更多
目的描述全球不同地区成人头颈部肿瘤的发病率和死亡率及其随时间的变化趋势。方法基于GLOBOCAN 2022数据库和全球疾病负担(Global Burden of Disease,GBD)2021数据库,计算不同性别、地区和人类发展指数(human development index,HDI)...目的描述全球不同地区成人头颈部肿瘤的发病率和死亡率及其随时间的变化趋势。方法基于GLOBOCAN 2022数据库和全球疾病负担(Global Burden of Disease,GBD)2021数据库,计算不同性别、地区和人类发展指数(human development index,HDI)等因素下的≥20岁成人头颈部肿瘤年龄标化发病率(age-standardized incidence rate,ASIR)和年龄标化死亡率(age-standardized mortality rate,ASMR),以及不同年龄组人群发病和死亡情况,并预测2040年成人头颈部肿瘤发病情况。结果2022年,全球≥20岁成人头颈部肿瘤新发病例估计值为1750871例、死亡病例估计值为527226例,其中发病率和死亡率最高的癌种分别为甲状腺癌(ASIR:14.9/10万)及唇、口腔和咽喉癌(ASMR:6.4/10万)。整体上,成年男性头颈部肿瘤的发病率(ASIR:32.8/10万比29.9/10万)和死亡率(ASMR:13.5/10万比4.4/10万)高于女性,尤以在唇、口腔、咽喉癌与鼻咽癌中差异最为突出,而女性甲状腺癌发病率(ASIR:22.3/10万比7.5/10万)和死亡率(ASMR:0.9/10万比0.6/10万)高于男性。2022年,甲状腺癌和鼻咽癌的发病率在高HDI地区较高,唇、口腔和咽喉癌则在中HDI地区更为常见,且中低HDI地区的不同癌种通常具有较高的死亡率。如发病率保持不变,预计2040年全球≥20岁成人头颈部肿瘤发病例数估计值为235.4万例,较2022年估计值增加34.4%。结论头颈部肿瘤已成为全球成人癌症发病与死亡的重要构成部分,其流行病学特征在不同性别、年龄、地区和癌种间存在显著差异,需针对高危人群及地区制定差异化的防控策略。展开更多
背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disabi...背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disability-adjusted life year,DALY)负担的比率及趋势,并与美国(United States,US)和英国(United Kingdom,UK)进行了比较。方法 本研究从GLOBOCAN 2020在线数据库、2019年全球疾病负担(global burden of disease,GBD)研究和五大洲癌症发病率plus数据库(Cancer Incidence in Five Continents plus database,CI5 plus)中获取中国、美国和英国的癌症发病率、死亡率和DALY数据。使用Joinpoint回归模型分析中国、美国和英国癌症发病率和死亡率的趋势,计算年度百分比变化(annual percent change,APC),并确定最佳拟合连接点。结果 2020年估算的中国新发癌症病例为4,568,754例,癌症死亡病例为3,002,899例。此外,在中国,癌症引起的DALY为67,340,309。与美国和英国相比,中国的癌症发病率更低,但癌症死亡率和DALY率更高。此外,中国的癌症谱正在发生变化,除了肝癌、胃癌、食管癌和宫颈癌的发病率高和负担沉重外,肺癌、乳腺癌、结直肠癌和前列腺癌的发病率和负担正在迅速增长。结论 中国的癌症谱正在从发展中国家向发达国家转变。人口老龄化和不健康生活方式将继续增加中国的癌症负担。因此,中国应参考发达国家已建立的癌症防控策略,并结合中国不同地区癌症类型的多样性,调整国家癌症控制政策。展开更多
近期,世界卫生组织/国际癌症中心团队在A Cancer Journal for Clinicians(CA)杂志发表了最新的全球癌症统计数据。这份全球癌症负担现状的报告重点阐述了185个国家的36种癌症的发病和死亡情况,分析了癌症的区域性差异,并预估全球2018年...近期,世界卫生组织/国际癌症中心团队在A Cancer Journal for Clinicians(CA)杂志发表了最新的全球癌症统计数据。这份全球癌症负担现状的报告重点阐述了185个国家的36种癌症的发病和死亡情况,分析了癌症的区域性差异,并预估全球2018年将新增1810万癌症病例和970万癌症死亡病例。北京市肿瘤防治研究办公室团队对该报告进行了整理,并结合中国肿瘤登记现况进行简要解读。展开更多
目的了解全球及中国最新的肝癌流行病学特征情况。方法本团队通过对2024年4月国际癌症研究机构团队在其旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布的《最新全球癌症统计报告》及近期中国疾病预防控制...目的了解全球及中国最新的肝癌流行病学特征情况。方法本团队通过对2024年4月国际癌症研究机构团队在其旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布的《最新全球癌症统计报告》及近期中国疾病预防控制中心国家慢性病和非传染性疾病控制与预防中心研究团队在Lancet Public Health上发表的《2005–2020年中国癌症负担变化》这2篇报告中的结果进行整理并做简要解读,分析了2018–2022年肝癌在全球和中国的流行趋势变化、2022年全球不同人类发展指数和收入水平国家肝癌的ASIRW(世界标准人口年龄标准化发病率)和ASMRW(世界标准人口年龄标准化死亡率)变化情况、2022年全球和中国不同年龄段肝癌的发病和死亡情况以及2005–2020年中国肝癌的疾病负担变化。结果2022年全球肝癌新发病例865269例,死亡病例757948例,是全球第6大新发癌症及第3大癌症致死病因。全球和中国2018–2022年肝癌发病和死亡情况均趋于平稳或呈下降趋势,它们在男性人群中均高于女性,而且在中国总体人群和男性人群中均明显高于全球。2022年肝癌ASIRW和ASMRW在高人类发展指数和中等偏上收入水平国家人群中均最高。全球及中国2022年的肝癌ASIRW和ASMRW均随年龄增长而增高。我国2005–2020年所有年龄段死亡例数、ASMRW、生命损失年和年龄标准化生命损失年率的平均年度百分比变化均为负值,提示各指标均呈现下降趋势,而2020年我国男性和女性的肝癌ASMRW均随年龄增长而增高。结论肝癌在中国和全球仍面临巨大的疾病负担,在未来贯彻落实肝癌一级和二级预防策略仍是防治肝癌的重要措施,同时仍需继续做好肝癌全程多学科规范化管理。展开更多
2024年4月,国际癌症研究机构在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布了最新全球癌症统计报告,全面阐述了2022年全球185个国家36种癌症的发病、死亡与疾病负担情况,描述了其中20个地区10种主要癌症的地理分布差...2024年4月,国际癌症研究机构在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布了最新全球癌症统计报告,全面阐述了2022年全球185个国家36种癌症的发病、死亡与疾病负担情况,描述了其中20个地区10种主要癌症的地理分布差异,同时根据2022年的发病与死亡数据预测了2050年全球癌症疾病负担。基于我国癌症流行现状及防治目标,北京大学肿瘤医院流行病学研究室团队对该报告进行了整理与解读。展开更多
目的通过及时了解2024年4月在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表的《2022全球癌症统计报告:全球185个国家36种癌症发病率和死亡率估计》中报告的全球癌症最新统计数据,为我国及时调整癌症预防及控制措施提...目的通过及时了解2024年4月在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表的《2022全球癌症统计报告:全球185个国家36种癌症发病率和死亡率估计》中报告的全球癌症最新统计数据,为我国及时调整癌症预防及控制措施提供参考。方法系统整理并分析了GLOBOCAN 2022中的统计数据,对分年龄、性别、类型及地区的癌症发病和死亡情况进行全面解读,重点对中国癌症与世界癌症水平的比较进行分析,并结合可能的危险因素流行情况和现行癌症预防及控制措施进行讨论。结果①从全球看,2022年全球新发癌症病例1997.6万例、标化发病率196.9/10万,死亡病例974.4万例、标化死亡率91.7/10万;所有癌症的标化发病率在欧洲最高(268.1/10万)、东南亚最低(109.6/10万),所有癌症的标化死亡率在欧洲最高(106.3/10万)、东南亚最低(71.0/10万);全球发病前3位的癌症分别是肺癌、乳腺癌、结直肠癌,死亡前3位的癌症分别是肺癌、结直肠癌、肝癌;所有癌症的标化发病率和标化死亡率均随年龄增长呈上升趋势。全球男性的新发病例数和标化发病率以及癌症死亡例数和标化死亡率均高于女性,肺癌和乳腺癌分别是男性和女性的第1位常见癌症和第1位癌症死亡原因。②在中国,2022年中国癌症新发病例482.5万例、标化发病率为201.6/10万,死亡病例257.4万例、标化死亡率96.5/10万,按标化发病率和标化死亡率顺位排序在185个国家中均位于第65位,癌症新发病例数顺位前3位者分别为肺癌、结直肠癌及甲状腺癌,癌症死亡例数顺位前3位者分别为肺癌、肝癌及胃癌。结论2022年全球癌症标化发病率和标化死亡率均较2020年(196.9/10万比201.0/10万、91.7/10万比100.7/10万)有所下降。我国新发癌症第1位与全球一致(均是肺癌),而第2、3位与全球不同,我国第2、3位分别是结直肠癌和甲状腺癌,全球第2、3位分别是乳腺癌和结直肠癌。我国与全球的首位癌症死因均为肺癌,而第2、3位与全球不同,我国第2、3位癌症死因分别为肝癌和胃癌,而全球第2、3位分别是结直肠癌和肝癌。通过对中国癌症与全球癌症的流行病学特征比较,了解了我国癌症负担的特点,为制定适合我国国情的癌症综合防治措施提供了科学依据。展开更多
Objective: The burden of gastric cancer(GC) across different age groups needs updating. We determined the GC global, regional, and national burden profiles and changes in incidence for 3 sequential 5-year intervals fr...Objective: The burden of gastric cancer(GC) across different age groups needs updating. We determined the GC global, regional, and national burden profiles and changes in incidence for 3 sequential 5-year intervals from 2003 to 2017.Methods: The latest incidence and mortality estimates of GC from 185 countries and regions were extracted from the GLOBOCAN 2022 database. The 5-year interval age-standardised incidence rates(ASIRs) were evaluated using cancer registry data from volumes X±XII of the Cancer Incidence in Five Continents(CI5). Correlation analysis was used to evaluate the relationship between ASIR or the age-standardised mortality rate(ASMR) and the Human Development Index(HDI).Results: There was an estimated global 968,000 new GC cases and 660,000 deaths in 2022, with male predominance. GC ASIRs and ASMRs were 9.2 and 6.1 per 100,000 persons, respectively. East Asia had the highest burden, with 53.8% of cases and 48.2% of deaths among all geographic regions. There was a significant correlation between ASIR and HDI. Over three 5-year intervals from 2003 to 2017, the incidence of GC notably decreased in most countries but peaked at 2008±2012 in New Zealand, Turkey, and South Africa. Several countries in Europe, Oceania, and America suggest an increasingly concerning trend among younger individuals, especially females.Conclusions: GC is a significant health issue, especially among males and in geographic regions with an HDI, such as eastern Asia. While the incidence of GC is decreasing in many countries due to prevention efforts and improved treatments, a rising trend persists among younger individuals. Comprehensive prevention strategies tailored to different age patterns are clearly needed.展开更多
BACKGROUND Digestive cancer has traditionally been thought of as a disease that mainly occurs in elderly individuals,and it has been ignored in young adults by both patients and physicians.AIM To describe the worldwid...BACKGROUND Digestive cancer has traditionally been thought of as a disease that mainly occurs in elderly individuals,and it has been ignored in young adults by both patients and physicians.AIM To describe the worldwide profile of digestive cancer incidence,mortality and corresponding trends among 20–39-year-olds,with major patterns highlighted by age,sex,development level,and geographical region.METHODS I performed a population-based study to quantify the burden of young adult digestive cancers worldwide.Global,regional,sex,and country-specific data estimates of the number of new cancer cases and cancer-associated deaths that occurred in 2020 were extracted from the GLOBOCAN Cancer Today database.To assess long-term trends in young adult digestive cancer,cancer incidence data and mortality data were obtained from the Cancer in Five Continents Plus database and the World Health Organization mortality database,respectively.The associations between the human development index(HDI)and digestive cancer burden in young adults were evaluated by linear regression analyses.RESULTS In 2020,there were an estimated 19292789 new cancer cases,resulting in 9958133 deaths worldwide,which equated to an age-standardized incidence rate(ASIR)of 5.16 and age-standardized mortality rate(ASMR)of 3.04,accounting for 12.24%of all new cancer cases and 25.26%of all cancer deaths occurring in young adults.The burden was disproportionally greater among males,with male:female ratios of 1.34 for incidence and 1.58 for mortality.The ASIRs were 2.1,1.4,and 1.0 per 100000 people per year,whereas the ASMRs were 0.83,1.1,and 0.62 per 100000 people per year for colorectal,liver,and gastric cancer,respectively.When assessed by geographical region and HDI levels,the cancer profile varied substantially,and a strong positive correlation between the mortality-to-incidence ratio of digestive cancer and HDI ranking was found(R^(2)=0.7388,P<0.001).CONCLUSION The most common digestive cancer types are colorectal,liver and gastric cancer.The global digestive cancer burden among young adults is greater among males and exhibits a positive association with socioeconomic status.The digestive cancer burden is heavy in young adults,reinforcing the need for primary and secondary prevention strategies.展开更多
文摘癌症是影响人类健康的主要疾病之一,其发病率和死亡率等数据的准确统计对于开展疾病预防及制定干预策略极为重要。GLOBOCAN是国际癌症研究机构(International Agency for Research on Cancer,IARC)的一个项目,统计了世界上185个国家/地区中的36种癌症发病率、死亡率和患病率等相关数据,并且数据会不断更新,为研究者做疾病预测及疾病负担分析提供了宝贵的资料。本文通过对GLOBOCAN数据库架构及数据分析方法的详细介绍,帮助需要的研究者快速获取数据库相关知识,高效快捷地开展相关研究。
文摘2024年2月国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了最新的全球癌症统计数据GLOBOCAN 2022,估计了全球185个国家/地区的36种癌症发病数/率、死亡数/率等最新数据,描述了不同国家/地区和性别下的癌症负担差异,并对至2050年的癌症负担进行了预测。GLOBOCAN 2022数据显示,2022年全球估计新发癌症19976499例,9743832例癌症患者死亡。肺癌是全球首位常见癌症,2022年发病例数为2480675例,占总体癌症发病的12.4%。其次是乳腺癌(11.5%)、结直肠癌(9.6%)、前列腺癌(7.3%)和胃癌(4.9%)。肺癌仍是导致癌症死亡的首要原因,估计有1817469例死亡,占总体癌症死亡的18.7%。其次是结直肠癌(9.3%)、肝癌(7.8%)、乳腺癌(6.8%)和胃癌(6.8%)。基于人口统计学的预测表明,到2050年,全球新增癌症病例将达到3528.1万例,与2022年相比增加76.6%。全球癌症发病和死亡具有明显的地区和性别差异。本文对更新的数据库中主要内容进行整理并加以解读。
文摘Background:The International Agency for Research on Cancer(IARC)released the latest estimates of the global burden of cancer.We present a comparison of cancer profiles between 2020 and 2022,leveraging data from the Global Cancer Statistics(GLOBOCAN).Methods:Cancer incidence and mortality data were sourced from two different years,2020 and 2022,in the GLOBOCAN database.We tracked changes in age-standardized incidence and mortality rates,as well as estimated numbers of new cancer cases and deaths of the 15 most common cancer types globally and in China between 2020 and 2022.Additionally,we conducted comparisons to assess alterations in the cancer burden and variations in mortality-to-incidence ratio(MIR)across different regions and countries for both 2020 and 2022.Results:Lung cancer remained the most common cancer and the leading cause of cancer death worldwide.The new cases of thyroid cancer witnessed a sharp increase in 2022.Conversely,the numbers of new cancer cases and deaths from stomach and esophageal cancer decreased significantly in 2022.The geographic distribution of cancer incidence and mortality across six continents in 2022 largely mirrored that of 2020.Higher Human Development Index(HDI)levels in countries corresponded with elevated rates of cancer incidence and mortality,consistent with the previous year.Among 185 countries or territories,China’s age-standardized incidence rate(ASIR)ranked 64th and its age-standardized mortality rate(ASMR)ranked 68th,aligning with global averages.Lung cancer continued to impose the greatest burden of incidence and mortality.Stomach,breast,and esophageal cancers showed declines in both case counts and ASIR.Noteworthy reductions in both ASMR and absolute mortality numbers were observed in liver,stomach,and esophageal cancers.The global MIR decreased from 0.516 in 2020 to 0.488 in 2022.MIR trends indicated an upward trajectory with decreasing HDI levels in both 2022 and 2020.While Canada,Germany,India,Italy,Japan,and the United Kingdom demonstrated increasing MIRs,China exhibited the most significant decrease,followed by Russia and the United States.Conclusions:The global landscape of cancer incidence and mortality in 2022 reflects ongoing trends observed in 2020.Cancer burdens vary notably across countries with differing socioeconomic statuses.Decreases in stomach,liver,and esophageal cancer cases and deaths signify progress in cancer control efforts.The decrease in the global MIRs highlights potential improvements in cancer management.
基金supported by the National Key Research and Development Program of China(No.2021YFC2500400)National Natural Science Foundation of China(Nos.82172894,82204121,and 82073287)+2 种基金Natural Science Foundation of Tianjin(No.23JCQNJC00800)China Postdoctoral Science Foundation(No.2023M742617)Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-009A).
文摘Background:Thyroid cancer(TC)is the most common malignancy of the endocrine system.This study aimed to assess the global distribution of TC incidence and mortality in 2022,as well as to predict the burden for the year 2050.Methods:Data from the GLOBOCAN 2022 database were used to analyze the age-standardized incidence and mortality rates of TC by sex,age group(<55 years and≥55 years),country,world region,and level of Human Development Index(HDI)for 185 countries.The predicted incidence and mortality burden for 2050 was calculated based on demographic projections.Results:In 2022,an estimated 821,214 new TC cases and 47,507 TC-related deaths occurred worldwide.The age-standardized incidence rates(ASIRs)and age-standardized mortality rates(ASMRs)were higher in women(ASIR:13.60 per 100,000;ASMR:0.53 per 100,000)than in men(ASIR:4.60 per 100,000;ASMR:0.35 per 100,000).The ASIR in high HDI countries was approximately ten times higher than that in low HDI countries for both sexes,with relatively similar ASMR across regions.Among 185 countries,China had the largest number of TC cases(accounting for 56.77% of total cases)and TC-related deaths(accounting for 24.35% of global TC-related deaths),with the highest ASIR in men(13.30 per 100,000).Worldwide,approximately 64.63% of TC cases occurred in populations under 55 years old,while nearly 82.99% of TC-related deaths occurred in populations aged 55 years and above.If the rates stay the same as in 2022,it is projected that approximately 1,100,000 new TC cases and 91,000 TC-related deaths will occur in 2050,indicating a 34.15% and 89.58% increase,respectively.Conclusions:TC is a highly frequent cancer worldwide with disparities across regions,genders,and age groups.Our results provide light on the worldwide TC disease burden and facilitate regionally customized prevention measures.
文摘目的 基于国际癌症研究机构发布的GLOBOCAN 2018、2020及2022版本,系统分析2018–2022年间全球及中国胰腺癌的发病和死亡情况,并总结其主要影响因素,为我国胰腺癌的防控策略制定与临床诊疗实践提供参考。方法 收集并整理GLOBOCAN数据库中胰腺癌的发病例数、死亡例数,以及粗发病率、粗死亡率、世界年龄标准化发病率(age-standardized incidence rate by world standard population,ASIRW)、世界年龄标准化死亡率(age-standardized mortality rate by world standard population,ASMRW)等指标;同时结合人类发展指数(human development index,HDI)、国家收入水平等社会经济学参数,对全球与中国胰腺癌在不同地区、不同年龄与不同性别中的分布特点进行比较分析。结果 从2018年至2022年,全球胰腺癌新发病例数由45.8万增至51.1万,粗发病率从5.4/10万上升至6.5/10万;死亡例数从43.2万上升至46.7万,粗死亡率从5.7/10万增至5.9/10万,ASMRW从4.4/10万下降至4.3/10万。中国胰腺癌新发病例数从11.6万增至11.9万,占全球的23.3%,粗发病率维持在(8~9)/10万;死亡例数从11.0万下降至10.6万,粗死亡率从7.8/10万降至7.5/10万,ASMRW从4.9/10万降至3.9/10万。2022年非常高HDI国家的胰腺癌ASIRW为7.9/10万,ASMRW为6.9/10万,远高于低HDI国家的1.4/10万、1.3/10万。胰腺癌发病呈明显年龄相关性,≥75岁组全球新发191 157例(粗发病率为63.3/10万),中国新发37 722例(粗发病率为51.2/10万);全球和中国的男性发病率和死亡率均高于女性。结论 胰腺癌正成为全球和中国重要的公共卫生挑战,其发病与死亡在未来仍可能继续攀升。应进一步加强控烟、肥胖管理、糖尿病监测等综合防控措施;针对高危人群开展早期筛查及规范化诊治对于提升胰腺癌生存率至关重要。完善全国肿瘤登记体系,并结合多学科协作模式,可为精准防治胰腺癌奠定坚实基础。
文摘背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disability-adjusted life year,DALY)负担的比率及趋势,并与美国(United States,US)和英国(United Kingdom,UK)进行了比较。方法 本研究从GLOBOCAN 2020在线数据库、2019年全球疾病负担(global burden of disease,GBD)研究和五大洲癌症发病率plus数据库(Cancer Incidence in Five Continents plus database,CI5 plus)中获取中国、美国和英国的癌症发病率、死亡率和DALY数据。使用Joinpoint回归模型分析中国、美国和英国癌症发病率和死亡率的趋势,计算年度百分比变化(annual percent change,APC),并确定最佳拟合连接点。结果 2020年估算的中国新发癌症病例为4,568,754例,癌症死亡病例为3,002,899例。此外,在中国,癌症引起的DALY为67,340,309。与美国和英国相比,中国的癌症发病率更低,但癌症死亡率和DALY率更高。此外,中国的癌症谱正在发生变化,除了肝癌、胃癌、食管癌和宫颈癌的发病率高和负担沉重外,肺癌、乳腺癌、结直肠癌和前列腺癌的发病率和负担正在迅速增长。结论 中国的癌症谱正在从发展中国家向发达国家转变。人口老龄化和不健康生活方式将继续增加中国的癌症负担。因此,中国应参考发达国家已建立的癌症防控策略,并结合中国不同地区癌症类型的多样性,调整国家癌症控制政策。
文摘近期,世界卫生组织/国际癌症中心团队在A Cancer Journal for Clinicians(CA)杂志发表了最新的全球癌症统计数据。这份全球癌症负担现状的报告重点阐述了185个国家的36种癌症的发病和死亡情况,分析了癌症的区域性差异,并预估全球2018年将新增1810万癌症病例和970万癌症死亡病例。北京市肿瘤防治研究办公室团队对该报告进行了整理,并结合中国肿瘤登记现况进行简要解读。
文摘目的了解全球及中国最新的肝癌流行病学特征情况。方法本团队通过对2024年4月国际癌症研究机构团队在其旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布的《最新全球癌症统计报告》及近期中国疾病预防控制中心国家慢性病和非传染性疾病控制与预防中心研究团队在Lancet Public Health上发表的《2005–2020年中国癌症负担变化》这2篇报告中的结果进行整理并做简要解读,分析了2018–2022年肝癌在全球和中国的流行趋势变化、2022年全球不同人类发展指数和收入水平国家肝癌的ASIRW(世界标准人口年龄标准化发病率)和ASMRW(世界标准人口年龄标准化死亡率)变化情况、2022年全球和中国不同年龄段肝癌的发病和死亡情况以及2005–2020年中国肝癌的疾病负担变化。结果2022年全球肝癌新发病例865269例,死亡病例757948例,是全球第6大新发癌症及第3大癌症致死病因。全球和中国2018–2022年肝癌发病和死亡情况均趋于平稳或呈下降趋势,它们在男性人群中均高于女性,而且在中国总体人群和男性人群中均明显高于全球。2022年肝癌ASIRW和ASMRW在高人类发展指数和中等偏上收入水平国家人群中均最高。全球及中国2022年的肝癌ASIRW和ASMRW均随年龄增长而增高。我国2005–2020年所有年龄段死亡例数、ASMRW、生命损失年和年龄标准化生命损失年率的平均年度百分比变化均为负值,提示各指标均呈现下降趋势,而2020年我国男性和女性的肝癌ASMRW均随年龄增长而增高。结论肝癌在中国和全球仍面临巨大的疾病负担,在未来贯彻落实肝癌一级和二级预防策略仍是防治肝癌的重要措施,同时仍需继续做好肝癌全程多学科规范化管理。
文摘2024年4月,国际癌症研究机构在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布了最新全球癌症统计报告,全面阐述了2022年全球185个国家36种癌症的发病、死亡与疾病负担情况,描述了其中20个地区10种主要癌症的地理分布差异,同时根据2022年的发病与死亡数据预测了2050年全球癌症疾病负担。基于我国癌症流行现状及防治目标,北京大学肿瘤医院流行病学研究室团队对该报告进行了整理与解读。
文摘目的通过及时了解2024年4月在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表的《2022全球癌症统计报告:全球185个国家36种癌症发病率和死亡率估计》中报告的全球癌症最新统计数据,为我国及时调整癌症预防及控制措施提供参考。方法系统整理并分析了GLOBOCAN 2022中的统计数据,对分年龄、性别、类型及地区的癌症发病和死亡情况进行全面解读,重点对中国癌症与世界癌症水平的比较进行分析,并结合可能的危险因素流行情况和现行癌症预防及控制措施进行讨论。结果①从全球看,2022年全球新发癌症病例1997.6万例、标化发病率196.9/10万,死亡病例974.4万例、标化死亡率91.7/10万;所有癌症的标化发病率在欧洲最高(268.1/10万)、东南亚最低(109.6/10万),所有癌症的标化死亡率在欧洲最高(106.3/10万)、东南亚最低(71.0/10万);全球发病前3位的癌症分别是肺癌、乳腺癌、结直肠癌,死亡前3位的癌症分别是肺癌、结直肠癌、肝癌;所有癌症的标化发病率和标化死亡率均随年龄增长呈上升趋势。全球男性的新发病例数和标化发病率以及癌症死亡例数和标化死亡率均高于女性,肺癌和乳腺癌分别是男性和女性的第1位常见癌症和第1位癌症死亡原因。②在中国,2022年中国癌症新发病例482.5万例、标化发病率为201.6/10万,死亡病例257.4万例、标化死亡率96.5/10万,按标化发病率和标化死亡率顺位排序在185个国家中均位于第65位,癌症新发病例数顺位前3位者分别为肺癌、结直肠癌及甲状腺癌,癌症死亡例数顺位前3位者分别为肺癌、肝癌及胃癌。结论2022年全球癌症标化发病率和标化死亡率均较2020年(196.9/10万比201.0/10万、91.7/10万比100.7/10万)有所下降。我国新发癌症第1位与全球一致(均是肺癌),而第2、3位与全球不同,我国第2、3位分别是结直肠癌和甲状腺癌,全球第2、3位分别是乳腺癌和结直肠癌。我国与全球的首位癌症死因均为肺癌,而第2、3位与全球不同,我国第2、3位癌症死因分别为肝癌和胃癌,而全球第2、3位分别是结直肠癌和肝癌。通过对中国癌症与全球癌症的流行病学特征比较,了解了我国癌症负担的特点,为制定适合我国国情的癌症综合防治措施提供了科学依据。
基金funded by the National Natural Science Foundation of China (Grant No. 82273721)the National Natural Science Foundation of China (Grant No. 81974492)+1 种基金the Capital’s Funds for Health Improvement and Research Conflict of interest statement (Grant No. 2024-1G-4023)CAMS Innovation Fund for Medical Sciences (CIFMS)(Grant No. 2021-I2M-C&T-B-049)。
文摘Objective: The burden of gastric cancer(GC) across different age groups needs updating. We determined the GC global, regional, and national burden profiles and changes in incidence for 3 sequential 5-year intervals from 2003 to 2017.Methods: The latest incidence and mortality estimates of GC from 185 countries and regions were extracted from the GLOBOCAN 2022 database. The 5-year interval age-standardised incidence rates(ASIRs) were evaluated using cancer registry data from volumes X±XII of the Cancer Incidence in Five Continents(CI5). Correlation analysis was used to evaluate the relationship between ASIR or the age-standardised mortality rate(ASMR) and the Human Development Index(HDI).Results: There was an estimated global 968,000 new GC cases and 660,000 deaths in 2022, with male predominance. GC ASIRs and ASMRs were 9.2 and 6.1 per 100,000 persons, respectively. East Asia had the highest burden, with 53.8% of cases and 48.2% of deaths among all geographic regions. There was a significant correlation between ASIR and HDI. Over three 5-year intervals from 2003 to 2017, the incidence of GC notably decreased in most countries but peaked at 2008±2012 in New Zealand, Turkey, and South Africa. Several countries in Europe, Oceania, and America suggest an increasingly concerning trend among younger individuals, especially females.Conclusions: GC is a significant health issue, especially among males and in geographic regions with an HDI, such as eastern Asia. While the incidence of GC is decreasing in many countries due to prevention efforts and improved treatments, a rising trend persists among younger individuals. Comprehensive prevention strategies tailored to different age patterns are clearly needed.
基金the Scientific Research Projects of Health Commission of Mianyang City,No.202012.
文摘BACKGROUND Digestive cancer has traditionally been thought of as a disease that mainly occurs in elderly individuals,and it has been ignored in young adults by both patients and physicians.AIM To describe the worldwide profile of digestive cancer incidence,mortality and corresponding trends among 20–39-year-olds,with major patterns highlighted by age,sex,development level,and geographical region.METHODS I performed a population-based study to quantify the burden of young adult digestive cancers worldwide.Global,regional,sex,and country-specific data estimates of the number of new cancer cases and cancer-associated deaths that occurred in 2020 were extracted from the GLOBOCAN Cancer Today database.To assess long-term trends in young adult digestive cancer,cancer incidence data and mortality data were obtained from the Cancer in Five Continents Plus database and the World Health Organization mortality database,respectively.The associations between the human development index(HDI)and digestive cancer burden in young adults were evaluated by linear regression analyses.RESULTS In 2020,there were an estimated 19292789 new cancer cases,resulting in 9958133 deaths worldwide,which equated to an age-standardized incidence rate(ASIR)of 5.16 and age-standardized mortality rate(ASMR)of 3.04,accounting for 12.24%of all new cancer cases and 25.26%of all cancer deaths occurring in young adults.The burden was disproportionally greater among males,with male:female ratios of 1.34 for incidence and 1.58 for mortality.The ASIRs were 2.1,1.4,and 1.0 per 100000 people per year,whereas the ASMRs were 0.83,1.1,and 0.62 per 100000 people per year for colorectal,liver,and gastric cancer,respectively.When assessed by geographical region and HDI levels,the cancer profile varied substantially,and a strong positive correlation between the mortality-to-incidence ratio of digestive cancer and HDI ranking was found(R^(2)=0.7388,P<0.001).CONCLUSION The most common digestive cancer types are colorectal,liver and gastric cancer.The global digestive cancer burden among young adults is greater among males and exhibits a positive association with socioeconomic status.The digestive cancer burden is heavy in young adults,reinforcing the need for primary and secondary prevention strategies.
